<\/span><\/strong><\/h4>\n<\/span><\/strong><\/h4>\nProf. Dr. Ancu\u021ba Codrina<\/span><\/strong>
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i<\/span><\/strong><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.7″ hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
Corela\u021bii clinico-serologice \u0219i implica\u021bii terapeuitce \u00een miozite<\/span>
\nAutor: Codrina Ancu\u0163a<\/span><\/p>\nCuvinte cheie: miozite, anticorpi specifici miozitelor, anticorpi asocia\u021bi miozitelor, pattern clinico-serologic, management<\/p>\n
Obiective: La interferen\u021ba dintre specialit\u0103\u021bi, miozitele r\u0103m\u00e2n prin excelen\u021b\u0103 un grup heterogen de afec\u021biuni autoimune inflamatorii sistemice, caracterizate de polimorfism etiologic, imunopatologic \u0219i serologic, ce se reflect\u0103 la nivel terapeutic.
\nMetode: Fie c\u0103 ne direc\u021bion\u0103m asupra spectrului dermatomiozitelor ce au ca numitor comun microangiopatia mediat\u0103 de complement, fie c\u0103 r\u0103m\u00e2nem \u00een categoria polimozitelor, rezultat al citotoxicit\u0103\u021bii celulare \u0219i distruc\u021biei non-necrotice musculare, miozitele se definesc printr-o patobiologie complex\u0103 ce are ca \u021bint\u0103 principal\u0103 musculatura scheletic\u0103, gener\u00e2nd distruc\u021bii tisulare caracteristice \u0219i alterarea performan\u021belor musculare.
\nRezutate: Identificarea profilului imunologic este mandatorie, oferind repere diagnostice, definind fenotipuri clinico-serologice, stabilind prognosticul \u0219i jalonand alegerea algoritmului \u0219i agentului terapeutic optim. Interesant\u0103 este clasificarea miozitelor \u00een diferite subtipuri clinico-serologice raportat la prezen\u021ba anticorpior specifici (Myositis Specific Antibodies, MSA) sau a celor asocia\u021bi (Myositis Associated Antibodies, MAA). Cu o serie de particularit\u0103\u021bi clar statuate, MSA \u0219i MAA orienteaz\u0103 dianosticul spre unul din cele patru mari sindroame \u2013 antisintetaz\u0103 (anti-Jo1 \u0219i non-Jo1 pozitiv\u0103), dermatomiozitic (anti-Mi2, anti-MDA, SAE, TIF pozitiv), miozita necrotic\u0103 autoimun\u0103 (anti-SRP sau anti-HMGR pozitiv\u0103) \u0219i, nu \u00een ultimul r\u00e2nd, sindroamele overlap miozit\u0103-sclerodermie, miozit\u0103-artrit\u0103 reumatoid\u0103, miozit\u0103-sindrom Sjogren sau \u00een cadrul bolii mixte de \u021besut conjunctiv.
\nDe altfel, noile crititerii de clasificare formulate de ACR\/EULAR pentru miopatiile inflamatorii idiopatice cu debut juvenil \u0219i la adult \u0219i a subgrupelor majore folosesc, al\u0103turi de date clinice, enzime musculare \u0219i, eventual, modific\u0103ri histologice, \u0219i serologia autoimun\u0103.
\nConcluzii: Finalmente, managementul acestor entit\u0103\u021bi reprezint\u0103 o provocare \u00een practic\u0103 dat fiind heterogenitatea clinico-serologic\u0103 \u0219i patogenic\u0103 \u0219i apartenen\u021ba la categoria orphan disease.<\/p>\n
Clinico-serological profiles and therapeutic pattern in patients with myositis<\/span>
\nAutor: Codrina Ancu\u0163a<\/span><\/p>\nKeywords: myositis, myositis specific antibodies, myositis associated antibodies, clinico-serologic profile, management<\/p>\n
Objectives: At the interference between specialties, myositis remains a heterogeneous group of systemic inflammatory autoimmune diseases characterized by an extreme etiological, immunopathological and serological polymorphism that is reflected at the therapeutic level.
\nMethods: Whether we focus on the spectrum of dermatomyositis typically classified as a complement-mediated microangiopathy, or we remain in the category of polymyositis as a result of cell-mediated cytotoxicity and non-necrotic muscle destruction, myositis is defined by a complex pathobiology targeting the skeletal muscle, generating characteristic tissue damage and impaired muscle performance.
\nResults: Identification of the immunological profile is mandatory, as it provides diagnostic guidelines, outlines clinical-serological phenotypes, indorses the prognosis and assist the choice of optimal algorithm and therapeutic agent. The classification of myositis into different clinical-serological subtypes classically rely on the presence of specific (Myositis Associated Antibodies, MSA) or associated antibodies (Myositis Associated Antibodies, MAA). MSA and MAA positivity direct the diagnosis towards one of the four major syndromes \u2013 antisynthetase syndrome (anti-Jo1 and non-Jo1 positive), dermatomyositis (anti-Mi2, anti-MDA, SAE, TIF positive), the newly described autoimmune necrotizing myositis (anti-SRP or anti-HMGR positive) and, last but not least, overlap syndromes myositis-scleroderma, myositis-rheumatoid arthritis, myositis-Sjogren’s syndrome or mixed connective tissue disease.
\nIn addition, the new classification criteria formulated by ACR \/ EULAR for idiopathic inflammatory myopathies with juvenile and adult onset and major subgroups rely on clinical parameters, muscle enzymes, histological changes, but also on autoimmune serology.
\nConclusion: Finally, the optimal management of myositis remains a challenge in daily practice clinical, based on serological and pathogenic heterogeneity.<\/p>\n
Scurt CV<\/span><\/p>\nProfesor universitar, Disciplina Reumatologie, Recuperare, Medicina Fizica si Balneologie, Universitatea de Medicina si Farmacie \u201cGrigore T. Popa\u201d Iasi.
\nMedic primar reumatologie si reabilitare, sef clinica Reumatologie 2, Spitalul Clinic Recuperare Iasi
\nCoordonator Centru EUSTAR 162, afiliat retelei EUSTAR (European Scleroderma Trials and Research Group),
\nCoordonator Centru Capilaroscopie \u2013 Network of imaging training center 2016-2021 (EULAR)
\nTraining in capilaroscopie (Paris, Franta 2004), ecografie musculoscheletala (Paris, Franta, 2004; Barcelona, Spania, 2008); osteodensitometrie DXA (Bucuresti, Romania, 2006).
\nMembru in societati stiintifice internationale:<\/strong> EUSTAR, IASP (International Association for the Study of Pain) si Special Interest Group Musculoskeletal Pain, SLEuro (European Lupus Society)
\nDomenii de interes:<\/strong> terapia biologica in patologia reumatismala imun mediata, orphan disease (Sclerodermia sistemica, miopatii inflamatorii idiopatice), sarcina si patologia reumatismala imun mediata[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” saved_tabs=”all” global_module=”9177″][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\nContacteaz\u0103 operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
![\"\"](\"https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2020\/02\/eventer_logo_150px.png\")
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464″ fullwidth=”on” _builder_version=”4.9.6″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Prof. Dr. Ancu\u021ba Codrina Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219iCorela\u021bii clinico-serologice \u0219i implica\u021bii terapeuitce \u00een miozite Autor: Codrina Ancu\u0163a Cuvinte cheie: miozite, anticorpi specifici miozitelor, anticorpi asocia\u021bi miozitelor, pattern clinico-serologic, management Obiective: La interferen\u021ba dintre specialit\u0103\u021bi, miozitele r\u0103m\u00e2n prin excelen\u021b\u0103 un grup heterogen de afec\u021biuni autoimune inflamatorii sistemice, caracterizate de polimorfism etiologic, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-8407","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=8407"}],"version-history":[{"count":8,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8407\/revisions"}],"predecessor-version":[{"id":9938,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8407\/revisions\/9938"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=8407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
Prof. Dr. Ancu\u021ba Codrina<\/span><\/strong>
\nUniversitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219i<\/span><\/strong><\/h4>\n[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”3.25″][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.7″ hover_enabled=”0″ sticky_enabled=”0″]<\/p>\n
Corela\u021bii clinico-serologice \u0219i implica\u021bii terapeuitce \u00een miozite<\/span>
\nAutor: Codrina Ancu\u0163a<\/span><\/p>\nCuvinte cheie: miozite, anticorpi specifici miozitelor, anticorpi asocia\u021bi miozitelor, pattern clinico-serologic, management<\/p>\n
Obiective: La interferen\u021ba dintre specialit\u0103\u021bi, miozitele r\u0103m\u00e2n prin excelen\u021b\u0103 un grup heterogen de afec\u021biuni autoimune inflamatorii sistemice, caracterizate de polimorfism etiologic, imunopatologic \u0219i serologic, ce se reflect\u0103 la nivel terapeutic.
\nMetode: Fie c\u0103 ne direc\u021bion\u0103m asupra spectrului dermatomiozitelor ce au ca numitor comun microangiopatia mediat\u0103 de complement, fie c\u0103 r\u0103m\u00e2nem \u00een categoria polimozitelor, rezultat al citotoxicit\u0103\u021bii celulare \u0219i distruc\u021biei non-necrotice musculare, miozitele se definesc printr-o patobiologie complex\u0103 ce are ca \u021bint\u0103 principal\u0103 musculatura scheletic\u0103, gener\u00e2nd distruc\u021bii tisulare caracteristice \u0219i alterarea performan\u021belor musculare.
\nRezutate: Identificarea profilului imunologic este mandatorie, oferind repere diagnostice, definind fenotipuri clinico-serologice, stabilind prognosticul \u0219i jalonand alegerea algoritmului \u0219i agentului terapeutic optim. Interesant\u0103 este clasificarea miozitelor \u00een diferite subtipuri clinico-serologice raportat la prezen\u021ba anticorpior specifici (Myositis Specific Antibodies, MSA) sau a celor asocia\u021bi (Myositis Associated Antibodies, MAA). Cu o serie de particularit\u0103\u021bi clar statuate, MSA \u0219i MAA orienteaz\u0103 dianosticul spre unul din cele patru mari sindroame \u2013 antisintetaz\u0103 (anti-Jo1 \u0219i non-Jo1 pozitiv\u0103), dermatomiozitic (anti-Mi2, anti-MDA, SAE, TIF pozitiv), miozita necrotic\u0103 autoimun\u0103 (anti-SRP sau anti-HMGR pozitiv\u0103) \u0219i, nu \u00een ultimul r\u00e2nd, sindroamele overlap miozit\u0103-sclerodermie, miozit\u0103-artrit\u0103 reumatoid\u0103, miozit\u0103-sindrom Sjogren sau \u00een cadrul bolii mixte de \u021besut conjunctiv.
\nDe altfel, noile crititerii de clasificare formulate de ACR\/EULAR pentru miopatiile inflamatorii idiopatice cu debut juvenil \u0219i la adult \u0219i a subgrupelor majore folosesc, al\u0103turi de date clinice, enzime musculare \u0219i, eventual, modific\u0103ri histologice, \u0219i serologia autoimun\u0103.
\nConcluzii: Finalmente, managementul acestor entit\u0103\u021bi reprezint\u0103 o provocare \u00een practic\u0103 dat fiind heterogenitatea clinico-serologic\u0103 \u0219i patogenic\u0103 \u0219i apartenen\u021ba la categoria orphan disease.<\/p>\n
Clinico-serological profiles and therapeutic pattern in patients with myositis<\/span>
\nAutor: Codrina Ancu\u0163a<\/span><\/p>\nKeywords: myositis, myositis specific antibodies, myositis associated antibodies, clinico-serologic profile, management<\/p>\n
Objectives: At the interference between specialties, myositis remains a heterogeneous group of systemic inflammatory autoimmune diseases characterized by an extreme etiological, immunopathological and serological polymorphism that is reflected at the therapeutic level.
\nMethods: Whether we focus on the spectrum of dermatomyositis typically classified as a complement-mediated microangiopathy, or we remain in the category of polymyositis as a result of cell-mediated cytotoxicity and non-necrotic muscle destruction, myositis is defined by a complex pathobiology targeting the skeletal muscle, generating characteristic tissue damage and impaired muscle performance.
\nResults: Identification of the immunological profile is mandatory, as it provides diagnostic guidelines, outlines clinical-serological phenotypes, indorses the prognosis and assist the choice of optimal algorithm and therapeutic agent. The classification of myositis into different clinical-serological subtypes classically rely on the presence of specific (Myositis Associated Antibodies, MSA) or associated antibodies (Myositis Associated Antibodies, MAA). MSA and MAA positivity direct the diagnosis towards one of the four major syndromes \u2013 antisynthetase syndrome (anti-Jo1 and non-Jo1 positive), dermatomyositis (anti-Mi2, anti-MDA, SAE, TIF positive), the newly described autoimmune necrotizing myositis (anti-SRP or anti-HMGR positive) and, last but not least, overlap syndromes myositis-scleroderma, myositis-rheumatoid arthritis, myositis-Sjogren’s syndrome or mixed connective tissue disease.
\nIn addition, the new classification criteria formulated by ACR \/ EULAR for idiopathic inflammatory myopathies with juvenile and adult onset and major subgroups rely on clinical parameters, muscle enzymes, histological changes, but also on autoimmune serology.
\nConclusion: Finally, the optimal management of myositis remains a challenge in daily practice clinical, based on serological and pathogenic heterogeneity.<\/p>\n
Scurt CV<\/span><\/p>\nProfesor universitar, Disciplina Reumatologie, Recuperare, Medicina Fizica si Balneologie, Universitatea de Medicina si Farmacie \u201cGrigore T. Popa\u201d Iasi.
\nMedic primar reumatologie si reabilitare, sef clinica Reumatologie 2, Spitalul Clinic Recuperare Iasi
\nCoordonator Centru EUSTAR 162, afiliat retelei EUSTAR (European Scleroderma Trials and Research Group),
\nCoordonator Centru Capilaroscopie \u2013 Network of imaging training center 2016-2021 (EULAR)
\nTraining in capilaroscopie (Paris, Franta 2004), ecografie musculoscheletala (Paris, Franta, 2004; Barcelona, Spania, 2008); osteodensitometrie DXA (Bucuresti, Romania, 2006).
\nMembru in societati stiintifice internationale:<\/strong> EUSTAR, IASP (International Association for the Study of Pain) si Special Interest Group Musculoskeletal Pain, SLEuro (European Lupus Society)
\nDomenii de interes:<\/strong> terapia biologica in patologia reumatismala imun mediata, orphan disease (Sclerodermia sistemica, miopatii inflamatorii idiopatice), sarcina si patologia reumatismala imun mediata[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” saved_tabs=”all” global_module=”9177″][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\nContacteaz\u0103 operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n
Operatorul PDI 2021<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n
<\/span><\/p>\n<\/span><\/p>\n<\/span><\/p>\nAdresa: Str. A. Panu nr. 13, Iasi<\/span>
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n[\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n
Parteneri Media<\/p>\n
[\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464″ fullwidth=”on” _builder_version=”4.9.6″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
Prof. Dr. Ancu\u021ba Codrina Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219iCorela\u021bii clinico-serologice \u0219i implica\u021bii terapeuitce \u00een miozite Autor: Codrina Ancu\u0163a Cuvinte cheie: miozite, anticorpi specifici miozitelor, anticorpi asocia\u021bi miozitelor, pattern clinico-serologic, management Obiective: La interferen\u021ba dintre specialit\u0103\u021bi, miozitele r\u0103m\u00e2n prin excelen\u021b\u0103 un grup heterogen de afec\u021biuni autoimune inflamatorii sistemice, caracterizate de polimorfism etiologic, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-8407","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=8407"}],"version-history":[{"count":8,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8407\/revisions"}],"predecessor-version":[{"id":9938,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8407\/revisions\/9938"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=8407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nAutor: Codrina Ancu\u0163a<\/span><\/p>\n
Cuvinte cheie: miozite, anticorpi specifici miozitelor, anticorpi asocia\u021bi miozitelor, pattern clinico-serologic, management<\/p>\n
Obiective: La interferen\u021ba dintre specialit\u0103\u021bi, miozitele r\u0103m\u00e2n prin excelen\u021b\u0103 un grup heterogen de afec\u021biuni autoimune inflamatorii sistemice, caracterizate de polimorfism etiologic, imunopatologic \u0219i serologic, ce se reflect\u0103 la nivel terapeutic.
\nMetode: Fie c\u0103 ne direc\u021bion\u0103m asupra spectrului dermatomiozitelor ce au ca numitor comun microangiopatia mediat\u0103 de complement, fie c\u0103 r\u0103m\u00e2nem \u00een categoria polimozitelor, rezultat al citotoxicit\u0103\u021bii celulare \u0219i distruc\u021biei non-necrotice musculare, miozitele se definesc printr-o patobiologie complex\u0103 ce are ca \u021bint\u0103 principal\u0103 musculatura scheletic\u0103, gener\u00e2nd distruc\u021bii tisulare caracteristice \u0219i alterarea performan\u021belor musculare.
\nRezutate: Identificarea profilului imunologic este mandatorie, oferind repere diagnostice, definind fenotipuri clinico-serologice, stabilind prognosticul \u0219i jalonand alegerea algoritmului \u0219i agentului terapeutic optim. Interesant\u0103 este clasificarea miozitelor \u00een diferite subtipuri clinico-serologice raportat la prezen\u021ba anticorpior specifici (Myositis Specific Antibodies, MSA) sau a celor asocia\u021bi (Myositis Associated Antibodies, MAA). Cu o serie de particularit\u0103\u021bi clar statuate, MSA \u0219i MAA orienteaz\u0103 dianosticul spre unul din cele patru mari sindroame \u2013 antisintetaz\u0103 (anti-Jo1 \u0219i non-Jo1 pozitiv\u0103), dermatomiozitic (anti-Mi2, anti-MDA, SAE, TIF pozitiv), miozita necrotic\u0103 autoimun\u0103 (anti-SRP sau anti-HMGR pozitiv\u0103) \u0219i, nu \u00een ultimul r\u00e2nd, sindroamele overlap miozit\u0103-sclerodermie, miozit\u0103-artrit\u0103 reumatoid\u0103, miozit\u0103-sindrom Sjogren sau \u00een cadrul bolii mixte de \u021besut conjunctiv.
\nDe altfel, noile crititerii de clasificare formulate de ACR\/EULAR pentru miopatiile inflamatorii idiopatice cu debut juvenil \u0219i la adult \u0219i a subgrupelor majore folosesc, al\u0103turi de date clinice, enzime musculare \u0219i, eventual, modific\u0103ri histologice, \u0219i serologia autoimun\u0103.
\nConcluzii: Finalmente, managementul acestor entit\u0103\u021bi reprezint\u0103 o provocare \u00een practic\u0103 dat fiind heterogenitatea clinico-serologic\u0103 \u0219i patogenic\u0103 \u0219i apartenen\u021ba la categoria orphan disease.<\/p>\n
Clinico-serological profiles and therapeutic pattern in patients with myositis<\/span> Keywords: myositis, myositis specific antibodies, myositis associated antibodies, clinico-serologic profile, management<\/p>\n Objectives: At the interference between specialties, myositis remains a heterogeneous group of systemic inflammatory autoimmune diseases characterized by an extreme etiological, immunopathological and serological polymorphism that is reflected at the therapeutic level. Scurt CV<\/span><\/p>\n Profesor universitar, Disciplina Reumatologie, Recuperare, Medicina Fizica si Balneologie, Universitatea de Medicina si Farmacie \u201cGrigore T. Popa\u201d Iasi. Contacteaz\u0103 operatorul PDI 2021<\/p>\n [\/et_pb_text][et_pb_contact_form email=”contact@pdi.ro\/2021\/2019″ submit_button_text=”Trimite mesajul” _builder_version=”4.9.4″ title_font=”||||||||” custom_button=”on” button_text_color=”#F0622A”][et_pb_contact_field field_id=”Name” field_title=”Nume” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Email” field_title=”Adresa de e-mail” field_type=”email” _builder_version=”3.19.4″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][et_pb_contact_field field_id=”Message” field_title=”Mesajul dvs.” field_type=”text” fullwidth_field=”on” _builder_version=”3.18.9″ button_text_size__hover_enabled=”off” button_one_text_size__hover_enabled=”off” button_two_text_size__hover_enabled=”off” button_text_color__hover_enabled=”off” button_one_text_color__hover_enabled=”off” button_two_text_color__hover_enabled=”off” button_border_width__hover_enabled=”off” button_one_border_width__hover_enabled=”off” button_two_border_width__hover_enabled=”off” button_border_color__hover_enabled=”off” button_one_border_color__hover_enabled=”off” button_two_border_color__hover_enabled=”off” button_border_radius__hover_enabled=”off” button_one_border_radius__hover_enabled=”off” button_two_border_radius__hover_enabled=”off” button_letter_spacing__hover_enabled=”off” button_one_letter_spacing__hover_enabled=”off” button_two_letter_spacing__hover_enabled=”off” button_bg_color__hover_enabled=”off” button_one_bg_color__hover_enabled=”off” button_two_bg_color__hover_enabled=”off”][\/et_pb_contact_field][\/et_pb_contact_form][\/et_pb_column][et_pb_column type=”2_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark”]<\/p>\n Operatorul PDI 2021<\/p>\n [\/et_pb_text][et_pb_text _builder_version=”4.0.11″ text_font=”||||||||”]<\/p>\n <\/span><\/p>\n <\/span><\/p>\n Adresa: Str. A. Panu nr. 13, Iasi<\/span> [\/et_pb_text][et_pb_text disabled_on=”off|off|off” _builder_version=”4.0.11″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” header_font=”||||||||” background_layout=”dark” locked=”off”]<\/p>\n Parteneri Media<\/p>\n [\/et_pb_text][et_pb_gallery gallery_ids=”7203,7204,9252,9464″ fullwidth=”on” _builder_version=”4.9.6″ transform_scale=”86%|86%” max_width=”63%” auto=”on” auto_speed=”3500″ hover_transition_duration=”100ms” hover_transition_delay=”50ms” hover_transition_speed_curve=”ease-in-out” locked=”off”][\/et_pb_gallery][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":" Prof. Dr. Ancu\u021ba Codrina Universitatea de Medicin\u0103 \u0219i Farmacie \u201cGrigore T. Popa\u201d Ia\u0219iCorela\u021bii clinico-serologice \u0219i implica\u021bii terapeuitce \u00een miozite Autor: Codrina Ancu\u0163a Cuvinte cheie: miozite, anticorpi specifici miozitelor, anticorpi asocia\u021bi miozitelor, pattern clinico-serologic, management Obiective: La interferen\u021ba dintre specialit\u0103\u021bi, miozitele r\u0103m\u00e2n prin excelen\u021b\u0103 un grup heterogen de afec\u021biuni autoimune inflamatorii sistemice, caracterizate de polimorfism etiologic, […]<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-8407","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/comments?post=8407"}],"version-history":[{"count":8,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8407\/revisions"}],"predecessor-version":[{"id":9938,"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/pages\/8407\/revisions\/9938"}],"wp:attachment":[{"href":"https:\/\/pdi.ro\/2021\/wp-json\/wp\/v2\/media?parent=8407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nAutor: Codrina Ancu\u0163a<\/span><\/p>\n
\nMethods: Whether we focus on the spectrum of dermatomyositis typically classified as a complement-mediated microangiopathy, or we remain in the category of polymyositis as a result of cell-mediated cytotoxicity and non-necrotic muscle destruction, myositis is defined by a complex pathobiology targeting the skeletal muscle, generating characteristic tissue damage and impaired muscle performance.
\nResults: Identification of the immunological profile is mandatory, as it provides diagnostic guidelines, outlines clinical-serological phenotypes, indorses the prognosis and assist the choice of optimal algorithm and therapeutic agent. The classification of myositis into different clinical-serological subtypes classically rely on the presence of specific (Myositis Associated Antibodies, MSA) or associated antibodies (Myositis Associated Antibodies, MAA). MSA and MAA positivity direct the diagnosis towards one of the four major syndromes \u2013 antisynthetase syndrome (anti-Jo1 and non-Jo1 positive), dermatomyositis (anti-Mi2, anti-MDA, SAE, TIF positive), the newly described autoimmune necrotizing myositis (anti-SRP or anti-HMGR positive) and, last but not least, overlap syndromes myositis-scleroderma, myositis-rheumatoid arthritis, myositis-Sjogren’s syndrome or mixed connective tissue disease.
\nIn addition, the new classification criteria formulated by ACR \/ EULAR for idiopathic inflammatory myopathies with juvenile and adult onset and major subgroups rely on clinical parameters, muscle enzymes, histological changes, but also on autoimmune serology.
\nConclusion: Finally, the optimal management of myositis remains a challenge in daily practice clinical, based on serological and pathogenic heterogeneity.<\/p>\n
\nMedic primar reumatologie si reabilitare, sef clinica Reumatologie 2, Spitalul Clinic Recuperare Iasi
\nCoordonator Centru EUSTAR 162, afiliat retelei EUSTAR (European Scleroderma Trials and Research Group),
\nCoordonator Centru Capilaroscopie \u2013 Network of imaging training center 2016-2021 (EULAR)
\nTraining in capilaroscopie (Paris, Franta 2004), ecografie musculoscheletala (Paris, Franta, 2004; Barcelona, Spania, 2008); osteodensitometrie DXA (Bucuresti, Romania, 2006).
\nMembru in societati stiintifice internationale:<\/strong> EUSTAR, IASP (International Association for the Study of Pain) si Special Interest Group Musculoskeletal Pain, SLEuro (European Lupus Society)
\nDomenii de interes:<\/strong> terapia biologica in patologia reumatismala imun mediata, orphan disease (Sclerodermia sistemica, miopatii inflamatorii idiopatice), sarcina si patologia reumatismala imun mediata[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.9.6″ background_color=”rgba(117,194,33,0.23)” background_image=”https:\/\/pdi.ro\/2021\/wp-content\/uploads\/2021\/05\/PDI2021_header_1920x550px.jpg” background_blend=”multiply” custom_padding=”54px|0px|0|0px|false|false” top_divider_style=”waves2″ top_divider_color=”#ffffff” top_divider_height=”155px” top_divider_height_tablet=”” top_divider_height_phone=”97px” top_divider_height_last_edited=”on|desktop” bottom_divider_style=”waves2″ bottom_divider_color=”#75c221″ bottom_divider_flip=”vertical” bottom_divider_height_tablet=”” bottom_divider_height_phone=”59px” bottom_divider_height_last_edited=”on|desktop” saved_tabs=”all” global_module=”9177″][et_pb_row column_structure=”3_5,2_5″ _builder_version=”3.25″ custom_padding=”61px|0px|69px|0px|false|false”][et_pb_column type=”3_5″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.9.4″ text_font=”Kaushan Script||||||||” text_text_color=”#f0622a” text_font_size=”30px” text_line_height=”1.2em” header_font=”||||||||” background_layout=”dark” text_font_size_tablet=”” text_font_size_phone=”” text_font_size_last_edited=”on|desktop”]<\/p>\n<\/span><\/p>\n
Tel.: 0332.40.88.00-05<\/span>
E-mail: inscrieri@primaderma.ro<\/a>
<\/span>Website:\u00a0<\/span>www.eventernet.ro<\/a><\/p>\n